Discover 2,012 paid clinical trials in Michigan. Search by city or condition to find a research study near you that matches your needs across various therapeutic areas.
Michigan offers access to numerous clinical research opportunities for both healthy volunteers interested in paid studies and those with specific health conditions. Research hubs in Detroit, Grand Rapids, and Ann Arbor are enrolling participants, providing access to innovative treatments and personalized care options.
Filter
1
Filter results
Results: 2,012
FeaturedActive & Responsive
A Study Evaluating the Effectiveness and Safety of Risdiplam Administered in Pediatric Patients With Spinal Muscular Atrophy Who Experienced a Plateau or Decline in Function After Gene Therapy
for
Muscular Atrophy, Spinal
Location: Philadelphia PA, Gainesville FL, Atlanta GA,
Sponsor: Hoffmann-La Roche
Sex: All
Age: 0 - 2
Code: NCT05861999
Recruiting
FeaturedActive & Responsive
A Study to Evaluate Safety, Pharmacokinetics, and Activity of GDC-7035 as a Single Agent and in Combination in Patients With Advanced Solid Tumors
for
Solid Tumor
Location: Boston MA, New Haven CT, The Bronx NY, Montreal,
Sponsor: Genentech, Inc.
Sex: All
Age: 18+
Code: NCT06619587
Phase1, Recruiting
FeaturedActive & Responsive
A Study to Assess the Efficacy and Safety of Induction and Maintenance Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease
for
Moderately to Severely Active Crohns Disease
Location: Boston MA, Providence RI, North Massapequa NY,
Sponsor: Hoffmann-La Roche
Sex: All
Age: 16 - 70+
Code: NCT06819878
Phase3, Recruiting
Featured
A Study to Evaluate Glofitamab as a Single Agent vs. Investigator's Choice in Participants With Relapsed/Refractory Mantle Cell Lymphoma
for
Lymphoma
Location: New Haven CT, Stony Brook NY, New Brunswick NJ,
Sponsor: Hoffmann-La Roche
Sex: All
Age: 18+
Code: NCT06084936
Phase3, Recruiting
Featured
A Study Evaluating the Effectiveness and Safety of Risdiplam Administered as an Early Intervention in Pediatric Participants With Spinal Muscular Atrophy After Gene Therapy
for
Muscular Atrophy, Spinal
Location: New York NY, Philadelphia PA, Gainesville FL,
Sponsor: Hoffmann-La Roche
Sex: All
Age: 0 - 2
Code: NCT05861986
Recruiting
Interested in new trials?
Get alerts for new trials in your area by subscribing now
Featured
Study to Evaluate Adverse Events and Efficacy of Intravenous (IV) Telisotuzumab Adizutecan in Combination With a PD-1 Immune Checkpoint Inhibitor in Adult Participants With Advanced or Metastatic Non-Squamous NSCLC With No Prior Treatment for Advanced Disease, and No Actionable Genomic Alterations
for
Non Small Cell Lung Carcinoma
Location: Boston MA, Shirley NY, East Brunswick NJ, Easton PA,
Sponsor: AbbVie
Sex: All
Age: 18+
Code: NCT06772623
Phase1, Phase2, Recruiting
Featured
A Study to Evaluate the Efficacy and Safety of Inavolisib in Combination With Phesgo Versus Placebo in Combination With Phesgo in Participants With PIK3CA-Mutated HER2-Positive Locally Advanced or Metastatic Breast Cancer
for
Metastatic Breast Cancer
Location: Moncton, Boston MA, Quebec, Montreal, Hyattsville MD,
Sponsor: Hoffmann-La Roche
Sex: All
Age: 18+
Code: NCT05894239
Phase3, Recruiting
Featured
A Study to Evaluate the Adverse Events, and Efficacy of Intravenous (IV) of Telisotuzumab Adizutecan in Combination With IV Oxaliplatin, Fluorouracil, Folinic Acid/Leucovorin, Bevacizumab, Panitumumab in Adult Participants With Metastatic Colorectal Cancer
for
Metastatic Colorectal Cancer
Location: Boston MA, New Haven CT, Montreal, Fairfax VA,
Sponsor: AbbVie
Sex: All
Age: 18+
Code: NCT06820463
Phase2, Recruiting
Featured
A Study to Assess the Efficacy and Safety of Induction Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease
for
Moderately to Severely Active Crohns Disease
Location: Providence RI, North Worcester MA, Lebanon NH,
Sponsor: Hoffmann-La Roche
Sex: All
Age: 16 - 70+
Code: NCT06819891
Phase3, Recruiting
Featured
A Study of Multiple Therapies in Biomarker-selected Participants With Resectable Stages IB-III Non-small Cell Lung Cancer (NSCLC)
for
Non-small Cell Lung Cancer
Location: Boston MA, New Haven CT, Lebanon NH, New York NY,
Sponsor: Genentech, Inc.
Sex: All
Age: 18+
Code: NCT04302025
Phase2, Recruiting
Featured
A Long Term Extension Study to Evaluate the Safety and Efficacy of Afimkibart (RO7790121) in Participants With Atopic Dermatitis
for
Atopic Dermatitis
Location: Camp Hill PA, Markham, Newmarket, Mississauga, Tampa FL,
Sponsor: Hoffmann-La Roche
Sex: All
Age: 18+
Code: NCT07223697
Phase2, Recruiting
Featured
A Study to Evaluate Adverse Events and Change in Disease Activity of Intravenous ABBV-706 Versus Standard of Care in Adult Participants With Relapsed/Refractory Small Cell Lung Cancer
for
Small Cell Lung Cancer
Location: Boston MA, Bethlehem PA, Fairfax VA, Winchester VA,
Sponsor: AbbVie
Sex: All
Age: 18+
Code: NCT07365241
Phase3, Recruiting
Featured
A Study Evaluating Adherence, Tolerability, and Patient Reported Outcomes of Giredestrant in Participants With ER+/HER2- Early Breast Cancer Who Are Intolerant to Adjuvant Aromatase Inhibitor Therapy (novERA Breast Cancer)
for
Early Breast Cancer
Location: Sterling Heights MI, Fountain Valley CA
Sponsor: Genentech, Inc.
Sex: Female
Age: 18+
Code: NCT07541079
Phase3, Recruiting
Featured
A Study to Assess Intravenous (IV) Telisotuzumab Adizutecan in Combination With Fluorouracil, Folinic Acid, and Oxaliplatin (FOLFOX) Compared to Standard of Care in Adult Participants With First-Line Metastatic Pancreatic Ductal Adenocarcinoma
for
Metastatic Pancreatic Ductal Adenocarcinoma, PDAC
Location: Philadelphia PA, Fairfax VA, Cleveland OH,
Sponsor: AbbVie
Sex: All
Age: 18+
Code: NCT07490301
Phase2, Phase3, Recruiting
Featured
A Study to Assess Adverse Events and Change in Disease Activity of Multiple Treatment Combinations With Intravenous Mirvetuximab Soravtansine in Adult Participants With Ovarian Cancer
Study to Evaluate Adverse Events, Optimal Dose, and Change in Disease Activity, With Livmoniplimab in Combination With Budigalimab Plus Chemotherapy Versus IV Infused Pembrolizumab Plus Chemotherapy in Adult Participants With Untreated Metastatic Non-Squamous Non-Small Cell Lung Cancer (NSCLC)
Study of ABBV-142 to Assess Adverse Events and Change in Disease Activity in Adult Participants With Idiopathic Pulmonary Fibrosis
for
Idiopathic Pulmonary Fibrosis
Location: Trois-Rivieres, Philadelphia PA, Richmond VA,
Sponsor: AbbVie
Sex: All
Age: 40+
Code: NCT07230288
Phase2, Recruiting
Featured
A Study to Assess the Adverse Events, Change in Disease Activity, and How Oral ABBV-711 Tablets Move Through the Body as a Monotherapy and in Combination With Intravenously Infused Budigalimab (ABBV-181), in Adults With Advanced Squamous Tumors
for
Advanced Squamous Tumors
Location: Montreal, Toronto, Huntersville NC, Grand Rapids MI,
Sponsor: AbbVie
Sex: All
Age: 18+
Code: NCT07241039
Phase1, Recruiting
Featured
A Study to Evaluate the Efficacy and Safety of Intravenous (IV) Prasinezumab in Participants With Early-Stage Parkinson's Disease
for
Parkinson's Disease
Location: Boston MA, New Haven CT, New York NY, Commack NY,
Sponsor: Hoffmann-La Roche
Sex: All
Age: 50 - 70+
Code: NCT07174310
Phase3, Recruiting
Featured
Study to Assess the Injection Burden, Adverse Events, Change in Disease Activity, and Long-Term Preservation of Visual Acuity of Surabgene Lomparvovec in Adult Participants With Neovascular Age-Related Macular Degeneration (nAMD)
for
Neovascular Age-related Macular Degeneration
Location: Portland ME, Little Silver NJ, Philadelphia PA,